Madiha Derouazi founded AMAL in 2012 as a spin-off from the University of Geneva, Switzerland.
She has been working on vector engineering and therapeutic cancer vaccines for over 10 years. She has a strong background in applied molecular and cellular biotechnology, with research interests at the interface of fundamental and translational research, the so called bench-to-bedside.
In the Laboratory of Tumour Immunology of the University of Geneva, she designed and characterized the CPP-based multi-epitopic cancer vaccine that is currently being progressed by AMAL Therapeutics.
Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland and a Master in Biotechnology Engineering from the University of Technology of Berlin, Germany.